FBRX Stock: Forte Biosciences, Inc. Stock Price, Analysis & Insights
Get live fbrx stock price $17.97, comprehensive Forte Biosciences, Inc. stock analysis, charts, news, and expert forecast. Real-time fbrx stock data and investment insights.
Loading chart...
Company Overview
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Company Information
- CEO
- Paul A. Wagner
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
Contact Information
- Website
- https://www.fortebiorx.com
- Address
- 3060 Pegasus Park Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.98)
Business Model & Strategy
Forte Biosciences, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Paul A. Wagner, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Forte Biosciences, Inc. competes in the Biotechnology within the broader Healthcare. With 223.4 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Forte Biosciences, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Forte Biosciences, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Forte Biosciences, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Forte Biosciences, Inc.
- ⚠Investors should consider how Forte Biosciences, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
223.42M
P/E Ratio
-224.62
Beta
2.98
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 223.42M market capitalization
- Trading Volume: 87.82K shares traded today
- Price Range: 52-week range of $4.90 - $28.68
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Forte Biosciences, Inc.
Forte Biosciences, Inc. (FBRX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 223.42M, the company represents a significant player in its market. The stock is currently trading at $17.97 with a positivedaily change of 24.02%.
The company's 14 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -224.62, beta of 2.98, and 52-week price range from $4.90 to $28.68when evaluating investment opportunities.
Why Invest in Forte Biosciences, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Paul A. Wagner
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.